This is a phase III randomised open-label clinical trial assessing virologic efficacy and safety of Dolutegravir-containing versus Efavirenz-containing ART regimens in HIV-1 infected pregnant women and their infants. Read more
Baylor-Uganda is participating in a multi-country “VESTED” (Virologic Efficacy and Safety of ART Combinations with TAF/TDF, EFV, and DTG) study that is comparing the safety and virologic efficacy of different antiretroviral therapy (ART) regimens during pregnancy and through 50 weeks of maternal and infant follow-up postpartum. HIV-1-infected pregnant women are initiated on either a Dolutegravir-containing or an Efavirenz-containing antiretroviral regimen at 14-28 weeks of gestation. For more details follow the link:

Primary results presented at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI) showed that;
• DTG-containing treatment regimens started at 14-28 weeks of pregnancy are safe and more effective for viral suppression during pregnancy than an EFV-containing regimen.
• These findings re-affirm current international recommendations for use of DTG among all populations, including pregnant women and people of childbearing potential.
• TAF appears to be safer than and as effective as TDF, in combination with DTG and FTC.
Details of the primary results can be found here: